Johnson & Johnson
Sells icotrokinra (Icotyde), an oral IL-23 receptor peptide for plaque psoriasis discovered with Protagonist.
Share price
$261
Up 37% over 12 monthsWhat analysts expect
Buy
Buy75%
Hold25%
Sell0%
Price target for the next 12 months
$275Up 8.3% compared with the current price
Price now $254Average targetLowest $210 to highest $320
25 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $98B
- Yearly profit
- $21B
- Company value
- $631B
Revenue and profit for the last twelve months reported.
Peptides in this book
- IcotrokinraPrescription
Recent news
- 2026-10-09 Two-year ICONIC-LEAD data reported for Icotyde in adults and adolescents with psoriasis PR Newswire
- 2026-10-02 Two-year ICONIC-TOTAL data show durable Icotyde response in hard-to-treat psoriasis PR Newswire
Prices are delayed and figures rounded. Not investment advice.